metricas

Vacunas

Sugerencias
Vacunas Association of C4 and CH50 levels with cough and rhinorrhea in COVID-19 patients...
Información de la revista
Vol. 25. Núm. 4.
Páginas 431-516 (Octubre - Diciembre 2024)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1367
Vol. 25. Núm. 4.
Páginas 431-516 (Octubre - Diciembre 2024)
Original article

Association of C4 and CH50 levels with cough and rhinorrhea in COVID-19 patients: A retrospective analysis in the Iranian population

Asociación de los niveles de C4 y CH50 con tos y rinorrea en pacientes con COVID-19: Un análisis retrospectivo en la población iraní
Visitas
1367
Seyed Ali Hashemia, Forouzan Rostamib, Babak Shaghaghia, Mahla Niknama, Elham Abania, Abdol Sattar Paghehc, Arezou Khosrojerdic, Fatemeh Rezaeia,
Autor para correspondencia
rezaeii1363@gmail.com

Corresponding author at: Islamic Azad University of Chalous Branch, Chalous, Iran.
a Department of Laboratory Science, Islamic Azad University, Chalous Branch, Chalous, Iran
b Department of Nursing, Faculty of Nursing and Midwifery, Islamic Azad University, Chalous Branch, Chalous, Iran
c Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Abstract
Introduction

The wide spectrum of COVID-19 symptoms, ranging from mild manifestations to severe pulmonary damage and mortality, prompted this study to investigate the relationship between clinical symptoms and complement system (CS) activation in COVID-19 patients.

Materials and method

This retrospective study focused on 100 PCR-positive COVID-19 individuals admitted to Imam Khomeini and Bu Ali hospitals in Sari City from April to June 2021. The levels of C3 and C4 proteins in their blood were measured using nephelometry, and CH50 tests were done with single radial immunodiffusion to determine the activity of CS.

Results

The study found that high blood pressure, smoking, and diabetes were the most common underlying conditions among the patients, with prevalence rates of 29%, 24%, and 23%, respectively. Positive correlations were found between C4 and CH50 levels and the presence of cough and rhinorrhea in the subjects. Stratifying patients into 2 groups based on cough or rhinorrhea revealed a significant difference in CH50.

Conclusion

The findings suggest that COVID-19 patients with hypertension or diabetes mellitus may benefit from targeting CS for disease management.

Keywords:
COVID-19
Complement system
Clinical symptoms
Underlying diseases
Iranian population
Resumen
Introducción

El amplio espectro de síntomas de COVID-19, que van desde manifestaciones leves hasta daño pulmonar severo y mortalidad, impulsó este estudio a investigar la relación entre los síntomas clínicos y la activación del sistema del complemento (CS) en pacientes con COVID-19.

Materiales y método

este estudio retrospectivo se centró en 100 personas con COVID-19 con PCR positiva admitidas en los hospitales Imam Khomeini y Bu Ali en la ciudad de Sari de abril a junio de 2021. Los niveles de proteínas C3 y C4 en la sangre se midieron mediante nefelometría y Se realizaron pruebas de CH50 con inmunodifusión radial única (SRID) para determinar la actividad de CS.

Resultados

El estudio encontró que la presión arterial alta, el tabaquismo y la diabetes eran las afecciones subyacentes más comunes entre los pacientes, con tasas de prevalencia del 29%, 24% y 23%, respectivamente. Se encontraron correlaciones positivas entre los niveles de C4 y CH50 y la presencia de tos y rinorrea en los sujetos. La estratificación de los pacientes en dos grupos según la tos o la rinorrea reveló una diferencia significativa en CH50.

Conclusión

Los hallazgos sugieren que los pacientes con COVID-19 con hipertensión o diabetes mellitus pueden beneficiarse al abordar la CS para el manejo de la enfermedad.

Palabras clave:
COVID-19
sistema del complemento
síntomas clínicos
enfermedades subyacentes
población iraní

Artículo

Opciones para acceder a los textos completos de la publicación Vacunas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1.]
M.A. Lauxmann, N.E. Santucci, A.M. Autrán-Gómez.
The SARS-CoV-2 coronavirus and the COVID-19 outbreak.
Int Braz J Urol, 46 (2020), pp. 6-18
[2.]
A.J. Kucharski, T.W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, et al.
Early dynamics of transmission and control of COVID-19: a mathematical modelling study.
Lancet Infect Dis, 20 (2020), pp. 553-558
[3.]
T.G. Ksiazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, et al.
A novel coronavirus associated with severe acute respiratory syndrome.
N Engl J Med, 348 (2003), pp. 1953-1966
[4.]
L. Zhang, Y. Liu.
Potential interventions for novel coronavirus in China: a systematic review.
J Med Virol, 92 (2020), pp. 479-490
[5.]
J. Pang, M.X. Wang, I.Y.H. Ang, S.H.X. Tan, R.F. Lewis, J.I.-P. Chen, et al.
Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review.
J Clin Med, 9 (2020), pp. 623
[6.]
J.F.-W. Chan, K.-H. Kok, Z. Zhu, H. Chu, K.K.-W. To, S. Yuan, et al.
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.
Emerg Microb Infect, 9 (2020), pp. 221-236
[7.]
C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, P.-R. Hsueh.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges.
Int J Antimicrob Agents, 55 (2020),
[8.]
A.S. Pagheh, A. Asghari, K.A. Romenjan, T. Mousavi, F. Abedi, A. Ziaee, et al.
Seroprevalence of SARS-COV-2 antibodies among health-care workers exposed to COVID-19 patients in a large reference hospital, Iran.
Iran J Microbiol, 14 (2022), pp. 138
[9.]
A.T. Huang, B. Garcia-Carreras, M.D. Hitchings, B. Yang, L.C. Katzelnick, S.M. Rattigan, et al.
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nat Commun, 11 (2020), pp. 4704
[10.]
Y. Ehteshaminia, S.F. Jalali, F. Jadidi-Niaragh, S.E. Enderami, A.S. Pagheh, E. Akbari, et al.
Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment.
[11.]
M.C. Carroll.
The complement system in regulation of adaptive immunity.
Nat Immunol, 5 (2004), pp. 981-986
[12.]
P.J. Lachmann, A. Davies.
Complement and immunity to viruses.
[13.]
H. Molina.
Complement and immunity.
Rheum Dis Clin, 30 (2004), pp. 1-18
[14.]
N.S. Merle, R. Noe, L. Halbwachs-Mecarelli, V. Fremeaux-Bacchi, L.T. Roumenina.
Complement system part II: role in immunity.
Front Immunol, 6 (2015), pp. 257
[15.]
R.F. Ritchie, G.E. Palomaki, L.M. Neveux, O. Navolotskaia.
Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.
J Clin Lab Anal, 18 (2004), pp. 9-13
[16.]
N. Roumande, J. Amini Mahabadi, A. Saremi, M.R. Nateghi, M. Sanaye Naderi, A. Zare.
Evaluation of complement system function and C3 and C4 levels in patients with recurrent spontaneous abortion.
Sarem J Med Res, 6 (2021), pp. 163-168
[17.]
A.M.M.D. Risitano, M. Huber-Lang, D. Yancopoulou, C. Garlanda, F. Ciceri, J.D. Lambris.
Complement as a target in COVID-19?.
[18.]
W.J. Guan, N.S. Zhong.
Clinical characteristics of Covid-19 in China. Reply.
N Engl J Med, 382 (2020), pp. 1861-1862
[19.]
L.E. Gralinski, T.P. Sheahan, T.E. Morrison, V.D. Menachery, K. Jensen, S.R. Leist, et al.
Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis.
[20.]
C. Davis, M. Gao, M. Nichols, R. Henao.
Predicting hospital utilization and inpatient mortality of patients tested for COVID-19.
[21.]
J.N. Al-Swiahb, M.A. Motiwala.
Upper respiratory tract and otolaryngological manifestations of coronavirus disease 2019 (COVID-19): a systemic review.
[22.]
K. Gaietto, M.C. Freeman, L.A. DiCicco, S. Rauenswinter, J.R. Squire, Z. Aldewereld, et al.
Asthma as a risk factor for hospitalization in children with COVID-19: a nested case-control study.
Pediatr Allergy Immunol, 33 (2022),
[23.]
B. Beken, G.K. Ozturk, F.D. Aygun, C. Aydogmus, H.H. Akar.
Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019.
Ann Allergy Asthma Immunol, 126 (2021), pp. 569-575
[24.]
C. Bruno, L.G. Locatello, M. Cilona, G. Fancello, A. Vultaggio, L. Maltagliati, et al.
Seasonal allergic rhinitis symptoms in relation to COVID-19.
[25.]
E. Vezir, M. Hizal, B. Cura Yayla, K. Aykac, A. Yilmaz, G. Kaya, et al.
Does aeroallergen sensitivity and allergic rhinitis in children cause milder COVID-19 infection?.
Allergy Asthma Proc, 42 (2021), pp. 522-529
[26.]
G. Engström, B. Hedblad, G. Berglund, L. Janzon, F. Lindgärde.
Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study.
J Human hypertens, 21 (2007), pp. 276-282
[27.]
E. Magen, J. Mishal, J. Paskin, Z. Glick, C. Yosefy, M. Kidon, et al.
Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein.
J Clin Hypertens (Greenwich, Conn), 10 (2008), pp. 677-683
[28.]
J. Chen, Y. Liu, J. Qin, C. Ruan, X. Zeng, A. Xu, et al.
Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study.
Postgrad Med J, 98 (2022), pp. 515-522
[29.]
G. Engström, B. Hedblad, K.F. Eriksson, L. Janzon, F. Lindgärde.
Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.
Diabetes, 54 (2005), pp. 570-575
[30.]
W. Guo, M. Li, Y. Dong, H. Zhou, Z. Zhang, C. Tian, et al.
Diabetes is a risk factor for the progression and prognosis of COVID-19.
Diabetes Metab Res Rev, 36 (2020),
[31.]
M. Nassar, A. Daoud, N. Nso, L. Medina, V. Ghernautan, H. Bhangoo, et al.
Diabetes mellitus and COVID-19: review article.
Diabet Metab Syndr, 15 (2021),
[32.]
S. Mubarik, X. Liu, E.S. Eshak, K. Liu, Q. Liu, F. Wang, et al.
The association of hypertension with the severity of and mortality from the COVID-19 in the early stage of the epidemic in Wuhan, China: a multicenter retrospective cohort study.
asdasdasd
Opciones de artículo
Herramientas